Roche's Inavolisib Breast Cancer Treatment Gets FDA Breakthrough Therapy Designation
By Pierre Bertrand
Roche said that the U.S. Food and Drug Administration has designated its Inavolisib breast cancer treatment as a breakthrough therapy.
A breakthrough therapy designation is given to accelerate the development and regulatory review of medicines intended to treat serious or life-threatening conditions where preliminary data shows the possibility of a substantial improvement over other existing therapies.
The designation follows phase three study results showing that the drug reduced by 57% the risk of death or the disease worsening, Roche said.
The treatment is also being investigates in two other company-sponsored Phase III clinical studies. The data from the study will be submitted to other global health authorities, including the European Medicines Agency, the Swiss drug maker said.
Write to Pierre Bertrand at pierre.bertrand@wsj.com
(END) Dow Jones Newswires
May 21, 2024 01:38 ET (05:38 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Is It Time to Ditch Your Money Market Fund for Longer-Term Bonds?
-
What’s Happening In the Markets This Week
-
4 Reasons Why Today’s Stock Market Is Delivering Impressive Performance
-
What Does Nvidia’s Stock Split Mean for Investors?
-
5 Undervalued Stocks to Buy as Their Stories Play Out
-
Markets Brief: Return of the Meme Stocks
-
It’s Been a Terrible Time for Bonds. Here’s Why You Should Own Them
-
Which AI Stocks Are Turning Hype Into Revenue?
-
Tesla: Shareholder Vote Reduces Key Person Risk
-
After Earnings, Is CrowdStrike Stock a Buy, a Sell, or Fairly Valued?
-
Adobe’s Strong Quarterly Results Drive Share Gains
-
What Does Broadcom’s Stock Split Mean for Investors?
-
5 Ultracheap Stocks to Buy With the Best Returns on Investment
-
Broadcom Earnings: AI Sales Growth Accelerates
-
Oracle Earnings: IaaS Signings More Than Make Up for Miss
-
This Undervalued Stock Is a Buy After Its Dividend Increase